1648843-04-2

Usage

Uses

Used in Pharmaceutical Industry:
2-[(5-[(4-fluorophenyl)carbamoyl]pyrimidin-2-ylsulfanyl)methyl]-4-(trifluoromethoxy)phenylboronic acid is used as a potential therapeutic agent for the treatment of various diseases. Its unique molecular structure may allow it to interact with specific biological targets, such as enzymes or receptors, which could be implicated in the pathogenesis of certain conditions. The compound's ability to modulate these targets may lead to the development of new drugs with improved efficacy and safety profiles.
Used in Chemical Research:
In the field of chemical research, 2-[(5-[(4-fluorophenyl)carbamoyl]pyrimidin-2-ylsulfanyl)methyl]-4-(trifluoromethoxy)phenylboronic acid can be employed as a starting material or intermediate for the synthesis of other complex organic molecules. Its unique functional groups and structural features may enable the development of novel chemical entities with diverse applications, such as new pharmaceuticals, agrochemicals, or advanced materials.
Used in Material Science:
The compound's structural characteristics may also make it a candidate for applications in material science. For instance, its electronic properties, such as its ability to form charge-transfer complexes or its potential for photoluminescence, could be exploited in the development of new materials for optoelectronics, sensors, or energy storage devices.

References

Zebala et al. (2015), WO2015/016938 Lu et al. (2017), Effective combinatorial immunotherapy for castration-resistant prostate cancer; Nature 542 728 Kargl et al. (2019), Neutrophil content predicts lymphocyte depletion and anti-PD1 treatment failure in NSCLC; JCI Insight 4 e130850 Sun et al. (2019), Inhibiting myeloid-derived suppressor cell trafficking enhances T cell immunotherapy; JCI Insight 4 e126853 Greene et al. (2020), Inhibition of MDSC Trafficking with SX-682, a CXCR1/2 Inhibitor, Enhances NK-Cell Immunotherapy in Head and Neck Cancer Models; Clin. Cancer Res. 26 1420

Upstream product

• 110099-99-5 2-CHLOROPYRIMIDINE-5-CARBONYLCHLORIDE 
• 1360598-99-7 2-chloro-pyrimidine-5-carboxylic acid (4-fluoro-phenyl)-amide 
• 371-40-4 4-fluoroaniline 
• 374068-01-6 2-bromopyrimidine-5-carboxylic acid 
• 1240496-04-1 2-mercapto-pyrimidine-5-carboxylic acid (4-fluoro-phenyl)-amide 

Relevant academic research and scientific papers

2-[5-[N-(4-FLUOROPHENYL)CARBAMOYL]PYRIMIDINE-2-ILSULFANYLMETHYL]-4-(TRIFLUOROMETHOXY)PHENYL BORONIC ACID

PROBLEM TO BE SOLVED: To provide a pyrimidine carboxamide compound useful as a medicine. SOLUTION: There is provided a compound shown by a formula SX-682. SELECTED DRAWING: None COPYRIGHT: (C)2019,JPOandINPIT

Effective combinatorial immunotherapy for castration-resistant prostate cancer

A significant fraction of patients with advanced prostate cancer treated with androgen deprivation therapy experience relapse with relentless progression to lethal metastatic castration-resistant prostate cancer (mCRPC). Immune checkpoint blockade using a

2- [5- [N- (4 -FLUOROPHENYL) CARBAMOYL] PYRIMIDIN- 2 - YLSULFANYLMETHYL] -4- (TRIFLUOROMET HOXY) PHENYL] BORONIC ACID

There is disclosed a pyrimidinecarboxamide compound useful as a pharmaceutical agent, synthetic processes, and pharmaceutical compositions which include the pyrimidinecarboxamide compound. More specifically, there is disclosed a CXCRl/2 inhibitor useful f

THIOPYRIMIDINECARBOXAMIDES AS CXCR1/2 MODULATORS

There is disclosed a pyrimidinecarboxamide compound useful as a pharmaceutical agent, synthetic processes, and pharmaceutical compositions which include the pyrimidinecarboxamide compound. More specifically, there is disclosed a CXCR1/2 inhibitor useful f